Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma.

ABSTRACT: Osteosarcoma is the most common primary solid malignancy of the bone, mainly affecting pediatric patients. The main clinical issues are chemoresistance and metastatic spread, leading to a survival rate stagnating around 60% for four decades. Here, we investigated the effect of simvastatin as adjuvant therapy on chemotherapy. Cell viability was assessed by the MTT test, and a combination index was evaluated by an isobologram approach. Cell motility was assessed by wound-healing assay. Cell-derived xenograft models were established in mice. FFPE tumor samples were assessed by immunohistochemistry. In vitro experiments indicate that simvastatin synergized the conventional chemotherapy drugs' inhibitory effect on cell viability. Functional assays reveal that simvastatin supplementation favored

SUBMITTER: Mangelinck A 

PROVIDER: S-EPMC8616540 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature